tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Fungemia D016469 2 associated lipids
Legionellosis D007876 3 associated lipids
Lung Abscess D008169 1 associated lipids
IgA Deficiency D017098 2 associated lipids
IgG Deficiency D017099 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
Alopecia Areata D000506 6 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Polymyositis D017285 1 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Blepharitis D001762 4 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Erythema Nodosum D004893 5 associated lipids
Sweet Syndrome D016463 1 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Deglutition Disorders D003680 2 associated lipids
Oral Ulcer D019226 1 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Epididymitis D004823 1 associated lipids
Orchitis D009920 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Citrullinemia D020159 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Hand Injuries D006230 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Lichen Sclerosus et Atrophicus D018459 2 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Pemphigus D010392 3 associated lipids
Mutism D009155 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Intestinal Atresia D007409 3 associated lipids
Priapism D011317 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Trichomonas Infections D014245 3 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
West Nile Fever D014901 1 associated lipids
Foot Ulcer D016523 4 associated lipids
Fibroadenoma D018226 2 associated lipids
Tinea Capitis D014006 1 associated lipids
Pancreatic Fistula D010185 2 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Lymphocele D008210 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Angiofibroma D018322 2 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Cheilitis D002613 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Optic Neuritis D009902 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Balanitis D001446 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Blackham A and Griffiths RJ The effect of FK506 and cyclosporin A on antigen-induced arthritis. 1991 Clin. Exp. Immunol. pmid:1718639
Carobbi A et al. Effect of splenectomy in combination with FK 506 and 15-deoxyspergualin on cardiac xenograft survival. 1991 Transplant. Proc. pmid:1703704
Kawauchi M et al. Plasma level of FK 506 in newborn goats and infant baboons. 1991 Transplant. Proc. pmid:1721267
Iwasaki K et al. Pharmacokinetic study of FK 506 in the rat. 1991 Transplant. Proc. pmid:1721268
Kay JE et al. Uptake of FK 506 by lymphocytes and erythrocytes. 1991 Transplant. Proc. pmid:1721269
Jain AB et al. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721270
Abu-Elmagd KM et al. Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1721271
Abu-Elmagd KM et al. Strategy of FK 506 therapy in liver transplant patients: effect of graft function. 1991 Transplant. Proc. pmid:1721272
Ericzon BG et al. Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. 1991 Transplant. Proc. pmid:1721273
Jain AB et al. Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. 1991 Transplant. Proc. pmid:1721274
McMichael J et al. Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. 1991 Transplant. Proc. pmid:1721275
Nelson PA et al. Effect of immunosuppressive drugs on cytokine gene transcription studied by message amplification phenotyping (MAPPing) polymerase chain reaction. 1991 Transplant. Proc. pmid:1721299
Dumont FJ et al. Up-regulation of gene expression by FK 506. 1991 Transplant. Proc. pmid:1721300
Rao P et al. Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. 1991 Transplant. Proc. pmid:1721301
DiLella AG and Craig RJ Characterization of the human FKBP-12 gene and related pseudogenes. 1991 Transplant. Proc. pmid:1721302
Kar S and Carr B Gene expression of FK 506-binding protein. 1991 Transplant. Proc. pmid:1721303
Connelly PR Thermodynamics of interaction of FK 506-binding protein and its ligands. 1991 Transplant. Proc. pmid:1721304
Donnelly JG and Soldin SJ Purification of a 50- to 58-kDa immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. 1991 Transplant. Proc. pmid:1721305
Rosborough SL et al. Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK 506 affinity chromatography. 1991 Transplant. Proc. pmid:1721306
Borg AJ and Kumagai M FK 506 and xenogeneic human anti-porcine cellular reactivity. 1991 Transplant. Proc. pmid:1721332
Fung J et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. 1991 Transplant. Proc. pmid:1721333
Winkler M et al. Use of FK 506 for treatment of chronic rejection after liver transplantation. 1991 Transplant. Proc. pmid:1721334
D'Alessandro AM et al. FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. 1991 Transplant. Proc. pmid:1721335
Lewis WD et al. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. 1991 Transplant. Proc. pmid:1721336
Woodle ES et al. FK 506: reversal of humorally mediated rejection following ABO-incompatible liver transplantation. 1991 Transplant. Proc. pmid:1721337
Shaw BW et al. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. 1991 Transplant. Proc. pmid:1721338
McDiarmid SV et al. FK 506 rescue therapy in liver transplantation: outcome and complications. 1991 Transplant. Proc. pmid:1721339
Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721363
van Hoek B et al. Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome. 1991 Transplant. Proc. pmid:1703343
Jensen CW et al. Pediatric renal transplantation under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721364
McCauley J et al. The question of FK 506 nephrotoxicity after liver transplantation. 1991 Transplant. Proc. pmid:1703344
Jordan ML et al. FK 506 conversion of renal allografts failing cyclosporine immunosuppression. 1991 Transplant. Proc. pmid:1721365
Alessiani M et al. Infections in adult liver transplant patients under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1703345
Offner G et al. FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. 1991 Transplant. Proc. pmid:1721366
Imai K et al. Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. 1991 Transplant. Proc. pmid:1703347
Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721367
Starzl TE et al. Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. 1991 Transplant. Proc. pmid:1703351
Darras FS et al. Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721368
Shapiro R et al. Kidney transplantation under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1703352
Todo S et al. Clinical small bowel or small bowel plus liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721369
Tzakis AG et al. Use of FK 506 in pediatric patients. 1991 Transplant. Proc. pmid:1703353
Fries D et al. Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. 1991 Transplant. Proc. pmid:1721370
Jain AB et al. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1703354
Freise CE et al. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. 1991 Transplant. Proc. pmid:1721397
Eidelman BH et al. Neurologic complications of FK 506. 1991 Transplant. Proc. pmid:1721398
DiMartini A et al. Psychiatric morbidity in liver transplant patients. 1991 Transplant. Proc. pmid:1721399
Lopez OL et al. Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. 1991 Transplant. Proc. pmid:1721400
Viebahn R et al. Hypoxic and reoxygenation injury in human and rat hepatocytes--influence of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721401
Morrisett JD et al. Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. 1991 Transplant. Proc. pmid:1721402
Takeda Y et al. Effect of FK 506 on the survival of rat small bowel allografts. 1991 Transplant. Proc. pmid:1721426
Fukuzawa M et al. Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation. 1991 Transplant. Proc. pmid:1721427
Ogasa N et al. Effect of FK 506 on growth of transplanted newborn rat intestine. 1991 Transplant. Proc. pmid:1721428
de Bruin RW et al. Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721429
Iwaki Y et al. Replacement of donor lymphoid tissue in small-bowel transplants. 1991 Lancet pmid:1707470
Langrehr JM et al. FK 506 inhibits nitric oxide production by cells infiltrating sponge matrix allografts. 1991 Transplant. Proc. pmid:1721430
Markus PM et al. Effects of in vivo treatment with FK506 on natural killer cells in rats. 1991 Transplantation pmid:1707562
Gotoh M et al. Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates. 1991 Transplant. Proc. pmid:1721431
Lin CS et al. FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. 1991 Cell. Immunol. pmid:1707760
Valdivia LA et al. Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721432
Vincent SH et al. Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. 1991 Biochem. Pharmacol. pmid:1708254
Wu GD et al. FK 506 inhibits the development of transplant arteriosclerosis. 1991 Transplant. Proc. pmid:1721433
Kitahara S et al. Lymphoproliferative disorders after FK 506. 1991 Lancet pmid:1708846
Kobayashi N et al. Effect of FK 506 on abdominal organ cluster transplantation in pigs. 1991 Transplant. Proc. pmid:1721434
Holechek MJ Medication review: FK 506. 1991 ANNA J pmid:1708982
Michnick SW et al. Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin. 1991 Science pmid:1709301
Van Duyne GD et al. Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. 1991 Science pmid:1709302
Lim SM and White DJ The pharmacology of immunosuppression. 1991 Ann. Acad. Med. Singap. pmid:1709344
Carroll PB et al. The use of FK 506 in new-onset type I diabetes in man. 1991 Transplant. Proc. pmid:1721458
McCauley J et al. FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. 1991 Transplant. Proc. pmid:1721459
Carrieri G et al. Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. 1991 Transplant. Proc. pmid:1721460
Deguchi K et al. Effects of FK 506 on acute experimental allergic encephalomyelitis. 1991 Transplant. Proc. pmid:1721461
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Bolton C The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisolone. 1991 Transplant. Proc. pmid:1721462
Vathsala A et al. The immunosuppressive antagonism of low doses of FK506 and cyclosporine. 1991 Transplantation pmid:1713361
McManus BM et al. Impact of FK 506 on myocarditis in the enteroviral murine model. 1991 Transplant. Proc. pmid:1721463
Kawano K et al. A protective effect of FK506 in ischemically injured rat livers. 1991 Transplantation pmid:1713362
Nossal GJ Summary of the First International FK 506 Congress: perspectives and prospects. 1991 Transplant. Proc. pmid:1721464
Armitage JM et al. Preliminary experience with FK506 in thoracic transplantation. 1991 Transplantation pmid:1713363
Staruch MJ et al. Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis. 1991 Int. J. Immunopharmacol. pmid:1721613
Lorber MI et al. A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. 1991 Transplantation pmid:1713364
Abu-Elmagd K et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. 1991 Transplantation pmid:1713365
Takada K et al. Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. 1991 J. Pharmacobio-dyn. pmid:1713626
Jin YJ et al. Molecular cloning of a membrane-associated human FK506- and rapamycin-binding protein, FKBP-13. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1713687
Unmasking immunosuppression. 1991 Lancet pmid:1717800
Ericzon BG et al. Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. 1991 Transplant. Proc. pmid:1703695
Markus PM et al. Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. 1991 Transplantation pmid:1718063
Kumano K et al. FK 506-induced nephrotoxicity in rats. 1991 Transplant. Proc. pmid:1703696
Ryu S and Yasunami Y The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. 1991 Transplantation pmid:1718064
Kuroki H et al. Morphological and immunological analysis of rats with long-term-surviving limb allografts induced by a short course of FK 506 or cyclosporine. 1991 Transplant. Proc. pmid:1703697
Jamieson NV et al. Orthotopic liver transplantation at Addenbrooke's Hospital Cambridge 1968 to 1991. 1991 Clin Transpl pmid:1726459
Starzl TE et al. Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. 1991 Transplantation pmid:1718068
Morris RE et al. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. 1991 Transplant. Proc. pmid:1703698
Takahara S et al. Survival of cardiac allograft in highly sensitized and nonsensitized rats treated with FK506. 1991 J Clin Lab Immunol pmid:1726566
Lane WS et al. Complete amino acid sequence of the FK506 and rapamycin binding protein, FKBP, isolated from calf thymus. 1991 J. Protein Chem. pmid:1718307
Goto S et al. Effect of FK 506 and cyclosporine on heart allograft survival in rats. 1991 Transplant. Proc. pmid:1703700
Stötter H and Lotze MT Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. 1991 Arch Surg pmid:1726819
James DG Which immunomodulator? 1991 Br J Clin Pract pmid:1718384
Flavin T et al. Initial experience with FK 506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts. 1991 Transplant. Proc. pmid:1703701
Karlsson H and Nässberger L FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. 1991 J Clin Lab Immunol pmid:1726895
Jiang H et al. Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703702